ArticleStroke2026
Ratio of Left Atrial and Ventricular Volume as New Marker of Atrial Cardiopathy and Stroke Risk.
Article in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial cardiopathy is an important cause of embolic stroke and a potential cause of cognitive impairment. Increased left atrial volume indexed to body surface area (LAVi) has been widely used as a marker for atrial cardiopathy. However, because physiological remodeling, for example, due to exercise, may also increase LAVi, it lacks specificity. Left atrial to ventricular volume (LA:LV) ratio has been suggested as an improved marker of atrial cardiopathy, allowing detection of imbalanced, pathological atrial remodeling. We investigated if LA:LV ratio is associated with different sequelae of atrial cardiopathy.
methodsWe analyzed data from 2 cohorts, the population-based UK Biobank cohort (n=38 848) and a cohort of patients with ischemic stroke from the University Hospital Zürich (n=1273). In the UK Biobank cohort, we compared the association of LAVi and LA:LV ratio with risk of incident ischemic stroke or transient ischemic attack ascertained from linked health records, using competing risks survival analysis. We also investigated the association with cognitive function using linear regression models. In the ischemic stroke patient cohort, we compared LAVi and LA:LV ratio for identifying atrial fibrillation/flutter as a cause of stroke.
resultsWhile LAVi was not significantly associated with risk of ischemic stroke/transient ischemic attack (adjusted hazard ratio, 1.11 [95% CI, 0.97-1.26];
conclusionsWe provide evidence that LA:LV ratio is a strong, novel marker of atrial cardiopathy. Hence, LA:LV ratio has the potential to improve the diagnosis of atrial cardiopathy, facilitating the prophylaxis of ischemic stroke and maintaining brain health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.